Dupixent® (Dupilumab) Phase 3 Results Show Sustained Efficacy For Up To One Year In Children 1 To 11 Years Of Age With Eosinophilic Esophagitis (Eoe)

Media coverage

• Title	Dupixent® (Dupilumab) Phase 3 Results Show Sustained Efficacy For Up To One Year In Children 1 To 11 Years Of Age With Eosinophilic Esophagitis (Eoe)
  Media name/outlet	MENAFN -Press Releases (English)
  Country/Territory	Jordan
  Date	22/10/23
  Persons	Mirna Chehade

• Title	Press Release: Dupixent® (Dupilumab) Phase 3 Results Show Sustained Efficacy For Up To One Year In Children 1 To 11 Years Of Age With Eosinophilic Esophagitis (Eoe)
  Media name/outlet	MENAFN -Press Releases (English)
  Country/Territory	Jordan
  Date	22/10/23
  Persons	Mirna Chehade